2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun

Cell & Gene Chief Editor, Erin Harris, welcomed Dr. Peter Marks, Director, CBER, FDA and Dr. Nicole Verdun, Super Office Director, CBER, FDA for a discussion on the evolving regulatory landscape in 2024 for cell and gene therapies. During the discussion, they covered improving communication with sponsors, increasing speed availability of cell and gene therapies by enabling manufacturing processes and standards development, and much more. Available on-demand thanks to the support of Thermo Fisher Scientific.